Original ArticlesSafety of High-Dose Naltrexone Treatment: Hepatic Transaminase Profiles Among OutpatientsKim, Suck Won MD*; Grant, Jon E. JD, MD*; Yoon, Gihyun MD*; Williams, Kyle A. BS*; Remmel, Rory P. PhD†Author Information From the *Department of Psychiatry, Medical School, and †Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN. Reprints: Suck Won Kim, MD, Department of Psychiatry, Medical School, University of Minnesota, F256/2A West, 2450 Riverside Avenue, Minneapolis, MN 55454-1495 (e-mail: email@example.com). Clinical Neuropharmacology: March-April 2006 - Volume 29 - Issue 2 - p 77-79 Buy Abstract Objectives: This study was carried out to test the hypothesis that the hepatic safety profile of prolonged high-dose oral naltrexone (150 mg/d) is acceptable if over-the-counter analgesic use is restricted. Methods: Data from 41 consecutive outpatients with impulse-control disorder receiving naltrexone therapy were analyzed. Results: The mean treatment duration was 328 days and the mean naltrexone dose was 142 mg/d. Pretherapy/posttherapy mean aspartate transaminase and alanine transaminase levels in the naltrexone-alone group were 21.79/22.54 and 21.74/21.49 U, respectively (all within reference range). Conclusions: Although limited in scope, these findings support the hypothesis that long-term use of high-dose oral naltrexone is safe in otherwise healthy patients with impulse-control disorders who restrict their intake of acetaminophen, aspirin, or nonaspirin nonsteroidal anti-inflammatory drugs (NSAID). However, confirming studies are needed. © 2006 Lippincott Williams & Wilkins, Inc.